二甲双胍联合胰岛素治疗妊娠期糖尿病的疗效

Effect of Metformin Combined with Insulin on Gestational Diabetes Mellitus

目的探讨对妊娠期糖尿病患者采用二甲双胍+胰岛素完成治疗后获得临床疗效。方法选取2018年1月—2021年3月收治的79例妊娠期糖尿病患者进行治疗研究,依据治疗方法不同分为常规组(39例,采用常规疗法+门冬胰岛素治疗)和研究组(40例,采用常规疗法+二甲双胍+门冬胰岛素治疗)。比较两组患者治疗总有效率、胰岛素抵抗能力及母婴结局。结果研究组治疗总有效率(95.00%)高于常规组(71.79%),差异有统计学意义(P<0.05);治疗前,研究组空腹胰岛素(FINS)、空腹血糖(FPG)、胰岛素抵抗指数(HOMA-IR)同常规组比较,差异无统计学意义(P>0.05);治疗后,研究组FINS、FPG、HOMA-IR水平分别为(10.07±1.03)mU/L、(6.11±0.62)mmol/L、(4.12±0.42)均低于常规组,差异有统计学意义(P<0.05);两组母婴结局比较,研究组10.00%优于常规组30.77%,差异有统计学意义(P<0.05)。结论二甲双胍+门冬胰岛素治疗方法联合应用,可显著提高患者治疗效果,有效改善胰岛素抵抗能力,促进患者总体预后水平。

Objective To explore the clinical efficacy of metformin+insulin in patients with gestational diabetes.Methods A total of 79 patients with gestational diabetes mellitus who were treated from January 2018 to March 2021 were selected for treatment research.According to different treatment methods,they were divided into a conventional group(39 cases,treated with conventional therapy+insulin aspart)and a study group(40 cases,treatment with conventional therapy+metformin+insulin aspart).The total effective rate,insulin resistance and maternal and infant outcomes were compared between the two groups.Results The total effective rate of the study group(95.00%)was higher than that of the conventional group(71.79%),and the difference was statistically significant(P<0.05).Before treatment,there were no significant differences in FINS,FPG and HOMA-IR between study group and conventional group(P>0.05).After treatment,the levels of FINS,FPG and HOMA-IR in the study group were(10.07±1.03)mU/L,(6.11±0.62)mmol/L and(4.12±0.42),lower than those in the conventional group,and the differences were statistically significant(P<0.05).The maternal and infant outcomes in the study group were 10.00%lower than those in the conventional group(30.77%),and the difference was statistically significant(P<0.05).Conclusion The combination of metformin and insulin aspartate can significantly improve the therapeutic effect,effectively improve insulin resistance,and promote the overall prognosis of patients.